The New Geography of Risk Runs Through the Batch Record

by Priya NairClinical and Regulatory Correspondent, HMND

Regionalized manufacturing is not a patriotic slogan and it is not a spreadsheet comfort blanket. It is a systems decision about where risk lives, who owns it, and whether the evidence chain can survive a transfer without turning into a polite fiction.

The week’s real signal

The week’s signal was not just that companies keep talking about dual sourcing. It was that resilience is still being built the old fashioned way: by diversifying suppliers, adding manufacturing partners, and re drawing the network so a single region does not get to hold the whole product hostage. Research on pharma supply chains keeps landing on the same hard truth, that resilience means the ability to anticipate, withstand, and recover from disruption while keeping product flowing to patients. That sounds neat until you remember that every extra node also adds another place where data can go stale, records can diverge, and ownership can get vague.

That is the part the market likes to skip. Dual sourcing is not courage in a slide deck. It is duplicate process knowledge, duplicate quality evidence, and duplicate release logic, all of which have to stay coherent when the first site coughs.

Where the transfer succeeds or quietly breaks

Picture the room where the deviation stays open because the batch became real in one system before it became real in another. MES says one thing, ERP says another, and QA is left reconciling genealogy after the fact. That is not regionalization working. That is a handoff problem with a passport.

When a company shifts production to a new region or adds a CMO, the question is not whether the site exists. It is whether the tech transfer package carries enough process understanding for the new site to reproduce the critical parameters, the control strategy, and the release evidence without inventing its own shadow version. A serious transfer has to answer who owns validation, who closes deviations, how the batch record is structured, and whether lot genealogy can still be traced cleanly across sites when the inspection questions start getting specific.

If those pieces are weak, regionalization does not lower risk. It exports it. The failure just changes accent.

The software boundary nobody can wish away

This is where pharma and IT stop being adjacent functions and become the same problem. A new region only reduces risk if the systems layer can prove continuity across site boundaries: MES master data, electronic batch records, quality event workflows, supplier qualification files, and validation evidence all have to agree on what happened, when it happened, and under which state the batch was actually made.

That is why “the system is validated” can be such a dangerous sentence. Validated against what, and owned by whom? If a CMO runs on a different MES instance, or if the interfaces between LIMS, ERP, and batch record systems are brittle, the transfer can create a second truth that looks compliant until deviation handling starts asking awkward questions. Batch genealogy then stops being a traceability feature and becomes a witness statement.

The more regions and CMOs you add, the more resilience depends on interoperability discipline. If the tech transfer package is incomplete, the MES data model is inconsistent, or validation ownership is fuzzy after onboarding, the backup site becomes a second source of uncertainty instead of a second source of supply.

The operator’s version of resilience

That is why I do not trust resilience stories that glide past the people who have to make the evidence stand up in an audit. Procurement can buy a second supplier. Operations can book capacity. But the quality team, the data integrity lead, and the manufacturing systems group are the ones who decide whether the second site is a genuine option or a decorative one with a good region code.

Marina would probably call this governance. Fine. In the room, it looks more like this: who updates the MES recipe, who owns the method transfer, who reconciles a deviation across sites, who keeps change control from splitting into local exceptions, and who can prove that the new region is making the same product under the same control strategy. That is where supply resilience stops being aspiration and becomes an operating system.

If this handoff problem is sitting on your desk, write to hello@example.com. We know where the evidence chain usually snaps.